Chargement en cours...
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Talimogene laherparepvec is a first-in-class intralesional oncolytic immunotherapy. In a recent Phase III trial (OPTiM), talimogene laherparepvec significantly improved durable response rate compared with subcutaneous granulocyte–macrophage colony-stimulating factor (GM-CSF). Overall response rate w...
Enregistré dans:
| Publié dans: | Cancer Immunol Immunother |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Berlin Heidelberg
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5445176/ https://ncbi.nlm.nih.gov/pubmed/28238174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-017-1967-1 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|